Site Editor
Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD
Posted: Friday, September 20, 2024
The phase III TROPION-Lung01 trial, conducted by Jacob Sands, MD, of Dana-Farber Cancer Institute, Boston, and colleagues, compared the TROP2 antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) with docetaxel in patients with non–small cell lung cancer (NSCLC). Although the study did not meet its second dual primary endpoint of overall survival, Dato-DXd showed a numerical improvement in overall survival over docetaxel in the full NSCLC analysis set. These study results were presented during the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC; Abstract OA08.03).
“In the prespecified nonsquamous NSCLC subgroup, Dato-DXd demonstrated a clinically meaningful trend toward prolonged overall survival compared with docetaxel,” the authors mentioned. “The overall safety and efficacy profile of Dato-DXd supports its use as a potential new therapeutic option for patients with nonsquamous NSCLC who are eligible for subsequent therapy.”
This global study randomly assigned 604 patients with NSCLC on a 1:1 basis to receive Dato-DXd (n = 299) or docetaxel (n = 305) every 3 weeks. A prespecified subgroup analysis included survival by histology, and the secondary endpoint was the frequency of treatment-related adverse events.
At the median follow-up of 23.1 months, the median overall survival in the Dato-DXd and docetaxel groups was 12.9 and 11.8 months, respectively. Of note, the median overall survival was numerically longer among patients with nonsquamous vs squamous histology, regardless of whether they were treated with Dato-DXd (14.6 vs 7.6 months) or docetaxel (12.3 vs 9.4 months).
In terms of toxicity, stomatitis (47% vs 16%) and nausea (34% vs 17%) were the only treatment-related adverse events reported more often with Dato-DXd vs docetaxel. Conversely, adverse events associated more often with docetaxel vs Dato-DXd were alopecia (35% vs 32%) and neutropenia (26% vs 5%). Of note, treatment discontinuation and grade 3 or higher treatment-related adverse events occurred more often among patients treated with docetaxel.
Disclosure: For full disclosures of the study authors, visit wclc2024.iaslc.org.
2024 World Conference on Lung Cancer
JNCCN Spotlights
